Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female \>= 28 years of age~* Confirmed diagnosis of cystic fibrosis~* Forced Expiratory Volume in 1 second (FEV1) \>= 40% predicted~* Clinically stable~* Ability to reproduce spirometry~* Ability to understand and sign the informed consent~Exclusion Criteria:~* Use of an investigational agent within 4-week period prior to Visit 1~* Chronic daily use of ibuprofen or other NSAIDS~* Chronic daily use of insulin,oral diabetic agents or oral hypoglycemic agents~* History of hypersensitivity to beta agonists~* History of hypersensitivity to glitazones~* Oxygen saturation\<92%~* Pregnant, breastfeeding or unwilling to practice acceptable birth control~* History of hemoptysis \>30cc per episode within 30 days prior to Visit 1~* Significant history of hepatic, cardiovascular, renal,neurologic, hematologic or peptic ulcer disease~* Serum Glutamic-Oxaloacetic Transaminase (SGOT)/(Serum Glutamic Pyruvic Transaminase (SGPT) \>3 times the upper limit of normal at screening, documented biliary cirrhosis,or portal hypertension~* Creatinine \> 1.8 mg/dL at screening~* Inability to swallow pills~* Presence or abnormality that in the opinion of the investigator would compromise the safety or the quality of the data~* Subjects who have routinely taken ibuprofen or other NSAIDS; prednisone or other systemic corticosteroids, or insulin, or oral diabetic agents within 4 weeks prior to visit 1 or who have taken these medications as needed within 72 hours prior to visit one will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pioglitazone (Type: EXPERIMENTAL): All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily Other names: Actos, Takeda

Based on this trial design, predict the completion outcome and termination type (if applicable).